FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Related Keywords

Paulag Oconnor , , International Primary Central Nervous System Lymphoma , Collaborative Group , International Workshop On Chronic Lymphocytic Leukemia , International Working Group , Nurix Therapeutics Inc , Nurix Therapeutics , International Workshop , Chronic Lymphocytic Leukemia , Lugano Classification ,